fosfomycin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
antibiotics, produced by Streptomyces strains 1243 23155-02-4

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • fosfomycin trometamol
  • fosfomycin
  • fosfomycin tromethamine
An antibiotic produced by Streptomyces fradiae.
  • Molecular weight: 138.06
  • Formula: C3H7O4P
  • CLOGP: -0.03
  • LIPINSKI: 0
  • HAC: 4
  • HDO: 2
  • TPSA: 70.06
  • ALOGS: -0.47
  • ROTB: 1
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
3 g O
8 g P

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 3 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 50 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 82 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 192.90 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 31 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 0.32 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 2 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 1 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 1.90 hours Lombardo F, Berellini G, Obach RS

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
kinase-safety-class ACVR2A,ACVR2B,ACVRL1,AKT3,ALK,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK4,CDK5,CDK9,CSF1R,DDR1,DYRK1B,EGFR,EIF2AK3,EPHB4,ERBB2,FLT1,FLT3,GRK2,GSK3B,ITK,JAK1,JAK2,JAK3,KDR,MAP2K6,MAP3K14,MAP3K21,MAP3K7,MAP4K1,MAPK10,MAPK7,MAPK9,MAPKAPK2,MTOR,NTRK1,NTRK2,PDK1,PDK2,PDK4,PIK3CB,PIK3CD,PIM2,PRKCD,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TGFBR1,TTK,ULK1,ZAP70 59
kinase-selectivity-class ACVRL1,AXL,CDK4,CDK9,EPHB4,GRK2,JAK2,MAP2K6,MAP3K14,PIK3CD,SYK,TEK,TGFBR1,ZAP70 14
pfas-class PFAS structural alert (1 = True, 0 = False) 0

Approvals:

DateAgencyCompanyOrphan
Dec. 19, 1996 FDA ZAMBON SPA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Cardiospasm 328.06 25.26 77 10532 3369 90614469
Palmoplantar keratoderma 326.71 25.26 77 10532 3430 90614408
Sleep terror 308.25 25.26 77 10532 4387 90613451
Pruritus genital 306.65 25.26 77 10532 4481 90613357
Atrial tachycardia 290.50 25.26 78 10531 5912 90611926
Carotid artery occlusion 281.43 25.26 77 10532 6265 90611573
Tension headache 268.56 25.26 77 10532 7432 90610406
Anosmia 256.39 25.26 79 10530 9769 90608069
Immunisation 245.47 25.26 56 10553 2157 90615681
Facial pain 233.74 25.26 79 10530 13103 90604735
Pain of skin 210.91 25.26 77 10532 16005 90601833
Subarachnoid haemorrhage 202.86 25.26 77 10532 17827 90600011
Vasculitis 188.54 25.26 78 10531 22615 90595223
Ventricular tachycardia 185.45 25.26 79 10530 24629 90593209
Muscle twitching 183.70 25.26 78 10531 24124 90593714
Blindness 176.70 25.26 78 10531 26490 90591348
Diplopia 167.74 25.26 77 10532 28637 90589201
Eye pruritus 166.94 25.26 77 10532 28950 90588888
Lip swelling 163.37 25.26 83 10526 38527 90579311
Hallucination 151.52 25.26 95 10514 65864 90551974
Transient ischaemic attack 143.50 25.26 79 10530 43097 90574741
Tinnitus 135.41 25.26 76 10533 43026 90574812
Disturbance in attention 131.76 25.26 77 10532 47032 90570806
Angioedema 118.58 25.26 81 10528 64795 90553043
Rash papular 113.91 25.26 53 10556 20302 90597536
Cognitive disorder 113.64 25.26 81 10528 69326 90548512
Dry skin 98.59 25.26 82 10527 87991 90529847
Intentional product misuse 91.22 25.26 79 10530 89525 90528313
Heart rate increased 90.42 25.26 87 10522 112815 90505023
Blood glucose increased 89.02 25.26 80 10529 95166 90522672
COVID-19 87.13 25.26 103 10506 168740 90449098
Drug reaction with eosinophilia and systemic symptoms 81.95 25.26 55 10554 42703 90575135
Amnesia 80.14 25.26 80 10529 108425 90509413
Myocardial infarction 79.87 25.26 79 10530 105893 90511945
Feeling abnormal 79.71 25.26 98 10511 167137 90450701
Dehydration 77.08 25.26 104 10505 194343 90423495
Tachycardia 76.11 25.26 93 10516 157580 90460258
Hyperhidrosis 71.70 25.26 84 10525 136221 90481617
Palpitations 68.18 25.26 82 10527 136646 90481192
Pathogen resistance 67.72 25.26 28 10581 8087 90609751
Visual impairment 63.74 25.26 78 10531 132287 90485551
Migraine 49.92 25.26 84 10525 190308 90427530
Muscular weakness 46.18 25.26 85 10524 206581 90411257
Tissue infiltration 40.61 25.26 11 10598 859 90616979
Memory impairment 40.18 25.26 78 10531 197166 90420672
Respiratory alkalosis 39.64 25.26 15 10594 3433 90614405
Stevens-Johnson syndrome 38.46 25.26 30 10579 29346 90588492
Anxiety 36.88 25.26 99 10510 309673 90308165
Agranulocytosis 35.87 25.26 31 10578 34971 90582867
Back pain 34.42 25.26 98 10511 317077 90300761
Skin maceration 32.33 25.26 7 10602 211 90617627
Malaise 31.65 25.26 144 10465 585842 90031996
Infusion related reaction 30.30 25.26 6 10603 416774 90201064
Congenital umbilical hernia 29.31 25.26 7 10602 329 90617509
Hepatic enzyme increased 28.87 25.26 4 10605 360732 90257106
Abdominal pain upper 28.81 25.26 95 10514 332579 90285259
Drug intolerance 27.63 25.26 9 10600 447582 90170256
Umbilical cord around neck 26.93 25.26 6 10603 207 90617631
Pericarditis 26.92 25.26 81 10528 270070 90347768
Systemic lupus erythematosus 26.75 25.26 5 10604 361891 90255947
Urosepsis 26.32 25.26 21 10588 21211 90596627
Pruritus 25.54 25.26 128 10481 541397 90076441
Nasopharyngitis 25.45 25.26 8 10601 407096 90210742

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Cardiospasm 340.98 44.93 77 7551 1830 42611877
Palmoplantar keratoderma 317.67 44.93 75 7553 2179 42611528
Pruritus genital 305.91 44.93 75 7553 2564 42611143
Sleep terror 298.22 44.93 75 7553 2851 42610856
Tension headache 286.74 44.93 75 7553 3339 42610368
Atrial tachycardia 281.68 44.93 77 7551 4063 42609644
Carotid artery occlusion 276.06 44.93 76 7552 4118 42609589
Facial pain 270.28 44.93 75 7553 4185 42609522
Anosmia 260.25 44.93 76 7552 5100 42608607
Immunisation 225.96 44.93 51 7577 1207 42612500
Pain of skin 219.00 44.93 74 7554 8006 42605701
Eye pruritus 204.90 44.93 77 7551 11335 42602372
Pericarditis 196.12 44.93 78 7550 13366 42600341
Muscle twitching 195.33 44.93 75 7553 11705 42602002
Lip swelling 188.98 44.93 84 7544 18969 42594738
Subarachnoid haemorrhage 183.75 44.93 76 7552 14396 42599311
Rash papular 180.93 44.93 71 7557 11740 42601967
Vasculitis 169.38 44.93 77 7551 18317 42595390
Blindness 167.89 44.93 76 7552 17902 42595805
Pathogen resistance 158.55 44.93 64 7564 11386 42602321
Diplopia 155.97 44.93 75 7553 20241 42593466
Migraine 142.90 44.93 76 7552 25338 42588369
Disturbance in attention 139.47 44.93 79 7549 29787 42583920
Amnesia 134.89 44.93 76 7552 28361 42585346
Tinnitus 130.96 44.93 75 7553 28863 42584844
Ventricular tachycardia 130.73 44.93 76 7552 30084 42583623
Alopecia 127.49 44.93 74 7554 29202 42584505
Transient ischaemic attack 122.84 44.93 76 7552 33663 42580044
Cognitive disorder 121.95 44.93 76 7552 34096 42579611
Visual impairment 115.16 44.93 80 7548 43033 42570674
Dry skin 109.17 44.93 81 7547 48257 42565450
Angioedema 106.89 44.93 76 7552 42401 42571306
Memory impairment 95.53 44.93 76 7552 50146 42563561
Palpitations 94.77 44.93 76 7552 50721 42562986
Heart rate increased 89.53 44.93 75 7553 53180 42560527
Hallucination 88.54 44.93 77 7551 57430 42556277
Drug resistance 83.20 44.93 60 7568 34188 42579519
Feeling abnormal 79.50 44.93 79 7549 69707 42544000
Intentional product misuse 77.87 44.93 74 7554 61826 42551881
Abdominal discomfort 70.98 44.93 77 7551 75178 42538529
COVID-19 70.64 44.93 95 7533 115853 42497854
Muscular weakness 69.44 44.93 80 7548 83418 42530289
Blood glucose increased 68.79 44.93 75 7553 73624 42540083
Peripheral swelling 66.02 44.93 81 7547 90189 42523518
Abdominal pain upper 58.58 44.93 73 7555 82536 42531171
Hyperhidrosis 56.37 44.93 75 7553 90437 42523270
Tachycardia 54.31 44.93 78 7550 101009 42512698
Chest pain 53.24 44.93 92 7536 139438 42474269
Intentional product use issue 50.15 44.93 63 7565 71770 42541937
Insomnia 47.77 44.93 80 7548 118173 42495534
Anxiety 44.97 44.93 78 7550 118482 42495225

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Cardiospasm 632.34 27.09 148 16919 4819 110567413
Palmoplantar keratoderma 610.02 27.09 146 16921 5241 110566991
Pruritus genital 582.28 27.09 146 16921 6376 110565856
Sleep terror 580.34 27.09 146 16921 6464 110565768
Atrial tachycardia 546.77 27.09 149 16918 9029 110563203
Carotid artery occlusion 531.45 27.09 147 16920 9418 110562814
Tension headache 526.04 27.09 146 16921 9472 110562760
Anosmia 501.58 27.09 149 16918 12323 110559909
Facial pain 467.04 27.09 148 16919 15191 110557041
Immunisation 443.05 27.09 102 16965 3081 110569151
Pain of skin 416.68 27.09 145 16922 19884 110552348
Subarachnoid haemorrhage 367.96 27.09 147 16920 29555 110542677
Muscle twitching 366.85 27.09 147 16920 29788 110542444
Eye pruritus 357.34 27.09 148 16919 32627 110539605
Vasculitis 347.74 27.09 149 16918 35724 110536508
Blindness 342.53 27.09 148 16919 36211 110536021
Lip swelling 331.47 27.09 160 16907 50507 110521725
Diplopia 316.14 27.09 146 16921 41748 110530484
Ventricular tachycardia 300.41 27.09 149 16918 49860 110522372
Disturbance in attention 272.99 27.09 150 16917 61845 110510387
Rash papular 268.48 27.09 115 16952 27524 110544708
Transient ischaemic attack 265.83 27.09 149 16918 63833 110508399
Tinnitus 262.49 27.09 145 16922 60395 110511837
Hallucination 237.56 27.09 164 16903 101268 110470964
Cognitive disorder 227.60 27.09 151 16916 87360 110484872
Dry skin 210.57 27.09 156 16911 107497 110464735
Pathogen resistance 210.27 27.09 85 16982 17587 110554645
Angioedema 209.12 27.09 150 16917 98350 110473882
Amnesia 200.01 27.09 150 16917 105258 110466974
Heart rate increased 170.90 27.09 156 16911 143678 110428554
Visual impairment 169.97 27.09 151 16916 134277 110437955
Blood glucose increased 167.86 27.09 149 16918 132347 110439885
Intentional product misuse 163.50 27.09 147 16920 132757 110439475
COVID-19 153.58 27.09 189 16878 244871 110327361
Feeling abnormal 153.21 27.09 163 16904 180548 110391684
Palpitations 148.22 27.09 151 16916 159061 110413171
Migraine 140.51 27.09 152 16915 171500 110400732
Myocardial infarction 126.55 27.09 152 16915 191931 110380301
Hyperhidrosis 124.68 27.09 149 16918 187149 110385083
Tachycardia 123.32 27.09 163 16904 226482 110345750
Memory impairment 117.08 27.09 148 16919 196796 110375436
Pericarditis 112.19 27.09 153 16914 218961 110353271
Dehydration 106.75 27.09 170 16897 279341 110292891
Muscular weakness 105.91 27.09 159 16908 248309 110323923
Drug resistance 97.56 27.09 76 16991 56298 110515934
Chest pain 71.02 27.09 170 16897 376205 110196027
Anxiety 70.71 27.09 161 16906 344917 110227315
Back pain 70.46 27.09 168 16899 370828 110201404
Abdominal pain upper 66.19 27.09 158 16909 348953 110223279
Insomnia 66.01 27.09 161 16906 360429 110211803
Alopecia 65.86 27.09 162 16905 364591 110207641
Peripheral swelling 58.23 27.09 165 16902 403869 110168363
Intentional product use issue 55.63 27.09 120 16947 247786 110324446
Malaise 54.23 27.09 226 16841 671593 109900639
Drug reaction with eosinophilia and systemic symptoms 50.79 27.09 63 17004 82032 110490200
Abdominal discomfort 49.27 27.09 153 16914 393705 110178527
Pruritus 47.18 27.09 196 16871 581364 109990868
Drug hypersensitivity 42.72 27.09 9 17058 454081 110118151
Adverse drug reaction 41.31 27.09 65 17002 105494 110466738
Conductive deafness 38.24 27.09 9 17058 299 110571933
Stevens-Johnson syndrome 37.37 27.09 41 17026 46860 110525372
Infusion related reaction 37.00 27.09 7 17060 381155 110191077
Pyrexia 36.41 27.09 250 16817 898015 109674217
Immunosuppressant drug level decreased 35.27 27.09 14 17053 2757 110569475
Weight increased 34.35 27.09 11 17056 419633 110152599
Toxic epidermal necrolysis 34.23 27.09 43 17024 56684 110515548
Joint swelling 33.86 27.09 13 17054 442832 110129400
Death 33.62 27.09 35 17032 698834 109873398
Tissue infiltration 31.46 27.09 10 17057 1033 110571199
Nasopharyngitis 31.12 27.09 11 17056 394350 110177882
Urinary tract inflammation 31.02 27.09 8 17059 390 110571842
Pseudomonas infection 30.68 27.09 29 17038 27824 110544408
Diarrhoea 29.80 27.09 287 16780 1139218 109433014
Dizziness 29.25 27.09 196 16871 697997 109874235
Hepatitis cholestatic 28.90 27.09 23 17044 17543 110554689
Musculoskeletal stiffness 27.45 27.09 5 17062 279817 110292415
Swelling 27.34 27.09 10 17057 351031 110221201

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC J01XX01 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIBACTERIALS FOR SYSTEMIC USE
OTHER ANTIBACTERIALS
Other antibacterials
ATC S02AA17 SENSORY ORGANS
OTOLOGICALS
ANTIINFECTIVES
Antiinfectives
MeSH PA D000890 Anti-Infective Agents
MeSH PA D000900 Anti-Bacterial Agents
CHEBI has role CHEBI:33282 antibacterial agent
CHEBI has role CHEBI:35441 antiinfective agent
CHEBI has role CHEBI:33281 antimicrobial agent
CHEBI has role CHEBI:35610 antineoplastic agent
CHEBI has role CHEBI:78379 EC 2.5.1.7 (UDP-<em>N</em>-acetylglucosamine 1-carboxyvinyltransferase) inhibitor

Related Drugs by ATC class:

J01XX Other antibacterials 12 drugs
bacitracinclofoctoldaptomycingepotidacinlefamulinlinezolidmandelic acidmethenaminenitroxolinespectinomycintedizolid phosphatexibornol
S02AA Antiinfectives 17 drugs
acetic acidaluminium acetotartrateboric acidcefmenoximechloramphenicolchlorhexidineciprofloxacinclioquinolgentamicinhydrogen peroxidemiconazoleneomycin show all 17 →

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Urinary tract infectious disease indication 68566005
Escherichia coli urinary tract infection indication 301011002
Enterococcus Urinary Tract Infection indication
Kidney disease contraindication 90708001 DOID:557
Pseudomembranous enterocolitis contraindication 397683000




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 0.54 acidic
pKa2 5.59 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
UDP-N-acetylglucosamine 1-carboxyvinyltransferase Enzyme INHIBITOR IC50 7 CHEMBL CHEMBL
UDP-N-acetylglucosamine 1-carboxyvinyltransferase 1 Enzyme WOMBAT-PK
UDP-N-acetylglucosamine 1-carboxyvinyltransferase 2 Enzyme WOMBAT-PK
UDP-N-acetylglucosamine 1-carboxyvinyltransferase Enzyme IC50 4.98 CHEMBL

External reference:

IDSource
4024047 VUID
N0000022052 NUI
D00925 KEGG_DRUG
78964-85-9 SECONDARY_CAS_RN
4021007 VANDF
4024047 VANDF
C0016610 UMLSCUI
CHEBI:28915 CHEBI
FCN PDB_CHEM_ID
CHEMBL1757 ChEMBL_ID
DB00828 DRUGBANK_ID
CHEMBL1200331 ChEMBL_ID
D005578 MESH_DESCRIPTOR_UI
446987 PUBCHEM_CID
3014 INN_ID
10813 IUPHAR_LIGAND_ID
2N81MY12TE UNII
142135 RXNORM
29490 MMSL
340066 MMSL
4765 MMSL
d04106 MMSL
004467 NDDF
004468 NDDF
108720006 SNOMEDCT_US
108721005 SNOMEDCT_US
372534005 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
FOSFOMYCIN TROMETHAMINE HUMAN PRESCRIPTION DRUG LABEL 1 50090-5826 POWDER 3 g ORAL ANDA 20 sections
Fosfomycin Tromethamine Human Prescription Drug Label 1 50090-6130 GRANULE, FOR SOLUTION 3 g ORAL ANDA 21 sections
Fosfomycin tromethamine Human Prescription Drug Label 1 59651-651 GRANULE, FOR SOLUTION 3 g ORAL ANDA 21 sections
Fosfomycin Tromethamine HUMAN PRESCRIPTION DRUG LABEL 1 60219-3955 GRANULE, FOR SOLUTION 3 g ORAL ANDA 19 sections
Fosfomycin Tromethamine Human Prescription Drug Label 1 67877-749 GRANULE, FOR SOLUTION 3 g ORAL ANDA 21 sections
Fosfomycin Tromethamine HUMAN PRESCRIPTION DRUG LABEL 1 68094-064 GRANULE 3 g ORAL ANDA 24 sections
FOSFOMYCIN TROMETHAMINE HUMAN PRESCRIPTION DRUG LABEL 1 69097-579 GRANULE, FOR SOLUTION 3 g ORAL ANDA 19 sections
FOSFOMYCIN TROMETHAMINE HUMAN PRESCRIPTION DRUG LABEL 1 69097-579 GRANULE, FOR SOLUTION 3 g ORAL ANDA 19 sections
FOSFOMYCIN TROMETHAMINE HUMAN PRESCRIPTION DRUG LABEL 1 70700-268 POWDER 3 g ORAL ANDA 20 sections
Fosfomycin Tromethamine HUMAN PRESCRIPTION DRUG LABEL 1 73289-0067 GRANULE, FOR SOLUTION 3 g ORAL ANDA 21 sections
Fosfomycin Tromethamine HUMAN PRESCRIPTION DRUG LABEL 1 81033-024 GRANULE, FOR SOLUTION 3 g ORAL ANDA 21 sections